Salazopyrin (Sulfasalazine): Uses, Dosage & Side Effects

What Is Salazopyrin and What Is It Used For?

Sulfasalazine was first synthesized in 1940 by the Swedish physician Dr. Nana Svartz, who was seeking a drug that would combine anti-inflammatory and antibacterial properties to treat rheumatoid arthritis. The molecule was designed by chemically linking sulfapyridine (a sulfonamide antibiotic) to 5-aminosalicylic acid (5-ASA, also known as mesalazine) via an azo bond. Although the drug was initially developed for rheumatoid arthritis, it was subsequently found to be remarkably effective in inflammatory bowel disease, particularly ulcerative colitis. Today, sulfasalazine remains one of the most widely used and cost-effective treatments for both conditions.

After oral administration, approximately 10–30% of sulfasalazine is absorbed intact from the small intestine. The majority of the dose passes into the colon, where colonic bacteria (azoreductases) cleave the azo bond, releasing two metabolites: sulfapyridine and 5-aminosalicylic acid (5-ASA). The 5-ASA component acts locally in the colonic mucosa, exerting its anti-inflammatory effect by inhibiting cyclooxygenase and lipoxygenase pathways, scavenging reactive oxygen species, and inhibiting the production of pro-inflammatory cytokines such as interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF-α). The sulfapyridine component is largely absorbed from the colon and undergoes hepatic acetylation and hydroxylation before being excreted renally.

The precise mechanism by which sulfasalazine exerts its disease-modifying effects in rheumatoid arthritis is not fully understood, but it is believed to involve multiple immunomodulatory pathways. These include inhibition of nuclear factor kappa B (NF-κB) activation, suppression of T-cell proliferation, reduction of immunoglobulin production by B-cells, and inhibition of pro-inflammatory mediators including prostaglandins and leukotrienes. The immunomodulatory effects are thought to be mediated primarily by the sulfapyridine component, which reaches systemic concentrations.

Sulfasalazine is indicated for the treatment of the following conditions:

• Ulcerative colitis: Induction and maintenance of remission in mild to moderate ulcerative colitis. Sulfasalazine is particularly effective in left-sided colitis and proctosigmoiditis and is recommended as a first-line treatment by both the European Crohn’s and Colitis Organisation (ECCO) and the American Gastroenterological Association (AGA).
• Crohn’s disease: Treatment of mild to moderate Crohn’s colitis (Crohn’s disease affecting the colon). Sulfasalazine is less effective for small bowel Crohn’s disease because the drug requires colonic bacteria for activation. International guidelines recommend it primarily for colonic disease.
• Rheumatoid arthritis: As a conventional disease-modifying antirheumatic drug (cDMARD) for the treatment of active rheumatoid arthritis. The American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR) include sulfasalazine among the first-line DMARD options, either as monotherapy or in combination with methotrexate and hydroxychloroquine (triple therapy).
• Psoriatic arthritis: Treatment of peripheral joint involvement in psoriatic arthritis, particularly when NSAIDs alone are insufficient.
• Pyoderma gangraenosum: A skin condition sometimes associated with inflammatory bowel disease, characterized by painful ulcerating lesions.
• Juvenile idiopathic arthritis: In some cases, sulfasalazine is used for polyarticular juvenile idiopathic arthritis (JIA) in children who have not responded to NSAIDs.

Sulfasalazine is included on the WHO Model List of Essential Medicines, reflecting its importance and wide availability globally. It is available as standard (uncoated) tablets and enteric-coated tablets (Salazopyrin EN). The enteric coating protects the tablet from dissolving in the stomach, reducing gastrointestinal side effects such as nausea and vomiting that are common with the standard formulation. Both formulations contain 500 mg of sulfasalazine per tablet.

What Should You Know Before Taking Salazopyrin?

Contraindications

There are specific situations in which sulfasalazine must not be used. Understanding these absolute contraindications is essential for safe medication use and helps prevent potentially serious adverse reactions.

• Allergy to sulfasalazine or its metabolites: Do not take sulfasalazine if you have a known hypersensitivity to sulfasalazine, its metabolites (sulfapyridine or 5-aminosalicylic acid), or any of the excipients in the formulation. This includes patients with a history of severe allergic reactions to any sulfonamide (sulfa drug) or to salicylates such as aspirin.
• Acute intermittent porphyria: Sulfasalazine is contraindicated in patients with acute intermittent porphyria, a rare genetic disorder affecting heme biosynthesis. Sulfonamides may precipitate acute attacks of porphyria, which can be life-threatening.
• Intestinal or urinary obstruction: Sulfasalazine should not be used in patients with intestinal or urinary tract obstruction, as the drug may accumulate and cause toxicity.

Warnings and Precautions

You should inform your doctor before taking sulfasalazine if any of the following conditions apply to you:

• Recurrent or chronic infections: Sulfasalazine may suppress certain immune functions. If you develop a new infection during treatment (e.g., fever, sore throat, malaise), contact your doctor immediately, as treatment may need to be interrupted.
• Impaired kidney or liver function: Sulfasalazine and its metabolites are processed by the liver and excreted by the kidneys. Dose adjustment or closer monitoring may be required in patients with pre-existing hepatic or renal impairment.
• Severe allergies or asthma: Patients with a history of severe allergic reactions or bronchial asthma may be at increased risk of hypersensitivity reactions to sulfasalazine.
• Glucose-6-phosphate dehydrogenase (G6PD) deficiency: Patients with G6PD deficiency are at increased risk of hemolytic anemia when taking sulfasalazine. Inform your doctor if you have this condition before treatment begins.
• Male fertility: Sulfasalazine can cause oligospermia (reduced sperm count) and reduced sperm motility in men. This effect is reversible, and sperm parameters typically normalize within 2–3 months of discontinuing the medication. Men who are planning to father a child should discuss this with their doctor, as switching to an alternative medication (such as mesalazine, which does not affect sperm) may be advisable.
• Blood disorders: Sulfasalazine can cause serious hematological adverse effects including agranulocytosis (severe reduction in white blood cells), aplastic anemia, and thrombocytopenia. Contact your doctor immediately if you develop symptoms such as sore throat, fever, unusual pallor, or a red or yellowish skin discoloration, as these may indicate blood or liver abnormalities requiring urgent investigation.

Pregnancy and Breastfeeding

Sulfasalazine crosses the placenta, and concentrations in the fetus may be comparable to those in the mother. While extensive clinical experience has not demonstrated a clear increase in congenital malformations, animal studies cannot entirely exclude risks. Major rheumatology and gastroenterology guidelines, including those from the British Society for Rheumatology (BSR), EULAR, and ECCO, generally consider sulfasalazine compatible with pregnancy when the clinical benefit outweighs the potential risk, particularly for maintaining disease remission.

However, sulfasalazine inhibits the absorption of folic acid, which is critical for preventing neural tube defects during early pregnancy. Therefore, women taking sulfasalazine who are pregnant or planning pregnancy should take high-dose folic acid supplementation (typically 5 mg daily rather than the standard 400 µg) before conception and throughout pregnancy, as advised by their doctor.

Small amounts of sulfasalazine and its metabolites pass into breast milk. There have been isolated reports of bloody diarrhea in breastfed infants whose mothers were taking sulfasalazine, although this is uncommon. The decision to breastfeed while taking sulfasalazine should be made in consultation with your doctor, weighing the benefits of breastfeeding against the potential risks to the infant, particularly in premature or jaundiced newborns.

Driving and Operating Machinery

No specific effects on the ability to drive or operate machinery have been observed with sulfasalazine at standard therapeutic doses. However, if you experience side effects such as headache, dizziness, or visual disturbances while taking this medication, you should exercise caution when driving or using machines until these effects have resolved.

How Does Salazopyrin Interact with Other Drugs?

Sulfasalazine has several clinically significant drug interactions that healthcare providers should be aware of when prescribing this medication. These interactions can affect the efficacy or safety of either sulfasalazine or the co-administered drug. Always inform your doctor, pharmacist, or nurse about all prescription medications, over-the-counter drugs, vitamins, herbal products, and dietary supplements you are currently taking.

Major Interactions

Minor Interactions

What Is the Correct Dosage of Salazopyrin?

The dosage of sulfasalazine varies depending on the condition being treated, disease severity, and individual patient factors. Your doctor will determine the appropriate dose for you. Always follow your doctor’s specific instructions. The following dosage information is based on international clinical guidelines and approved product labeling.

Adults – Inflammatory Bowel Disease

Adults – Rheumatoid Arthritis

Children

Dosing for children is based on body weight and is determined by the treating physician. Sulfasalazine is generally used in children for ulcerative colitis and, less commonly, for juvenile idiopathic arthritis. The pediatric dose is typically calculated at 40–60 mg/kg/day for inflammatory bowel disease, divided into 3–6 equal doses taken with meals. For juvenile idiopathic arthritis, the dose is usually 30–50 mg/kg/day, titrated gradually. Children should be monitored closely for side effects, and regular blood tests are essential.

Elderly Patients

No specific dose adjustment is routinely required for elderly patients. However, elderly patients are more likely to have impaired kidney and liver function, and they may be more susceptible to adverse effects, particularly gastrointestinal and hematological side effects. Close monitoring and cautious dose titration are recommended. Your doctor will assess your kidney and liver function before starting treatment and adjust the dose if necessary.

Missed Dose

If you forget to take a dose of sulfasalazine, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten one. It is important to continue taking sulfasalazine for as long as your doctor has prescribed, even if you feel well, as stopping treatment prematurely may cause your condition to relapse or worsen. Sulfasalazine is typically taken as a long-term medication.

Overdose

Symptoms of sulfasalazine overdose may include nausea, vomiting, abdominal pain, and diarrhea. In cases of significant overdose, more serious symptoms such as drowsiness, seizures, metabolic acidosis, and crystalluria (crystal formation in the urine causing kidney damage) may occur. Hematological abnormalities, including hemolytic anemia and methemoglobinemia (reduced oxygen-carrying capacity of the blood), may also develop. Treatment is supportive, with emphasis on maintaining adequate hydration and urine output to prevent renal complications. Gastric lavage may be considered in cases of recent ingestion. There is no specific antidote for sulfasalazine overdose.

What Are the Side Effects of Salazopyrin?

Like all medications, sulfasalazine can cause side effects, although not everyone experiences them. Side effects are most common during the first three months of treatment and are often related to the sulfapyridine component of the drug. Many minor side effects can be managed by gradually increasing the dose, switching to the enteric-coated formulation (Salazopyrin EN), or adjusting the timing of doses. The following section classifies potential side effects by frequency based on regulatory data and clinical experience.

If you develop an infection with symptoms such as fever combined with significantly impaired general condition, or fever with local infection symptoms such as sore throat, mouth pain, or difficulty urinating, seek medical attention urgently so that a blood test can exclude agranulocytosis (severe deficiency of white blood cells). It is important to inform your doctor that you are taking sulfasalazine.

If you experience any adverse effects while taking sulfasalazine, even if they are not listed here, you can report them to your national pharmacovigilance authority (e.g., the MHRA Yellow Card scheme in the UK, the FDA MedWatch program in the US, or the EMA EudraVigilance system in Europe). Reporting helps monitor the ongoing safety of medicines.

How Should You Store Salazopyrin?

Proper storage of sulfasalazine is important to ensure the medication remains effective and safe for use. Follow these storage guidelines:

• Temperature: Store at room temperature, below 25°C (77°F). Do not freeze. Avoid exposure to excessive heat or direct sunlight, as this may affect the stability of the active ingredient.
• Container: Keep the tablets in the original container with the lid tightly closed. The characteristic yellow color of the tablets is normal and does not indicate degradation.
• Moisture protection: Protect from moisture. Do not store in bathrooms or other humid environments, as moisture can affect the enteric coating of EN tablets.
• Child safety: Keep all medications securely out of the sight and reach of children. The yellow tablets may be mistaken for candy by young children.
• Expiry date: Do not use sulfasalazine after the expiry date stated on the packaging. The expiry date refers to the last day of the stated month.
• Disposal: Do not dispose of medications via household waste or down drains. Return unused or expired sulfasalazine to your local pharmacy for safe, environmentally responsible disposal.

If the tablets appear damaged, discolored (beyond their normal yellow color), crumbled, or have an unusual odor, do not use them and consult your pharmacist for replacement.

What Does Salazopyrin Contain?

All Salazopyrin formulations contain sulfasalazine as the active pharmaceutical ingredient at a strength of 500 mg per tablet. Sulfasalazine is a yellow, crystalline powder with limited water solubility. The inactive ingredients (excipients) differ slightly between the standard tablet and the enteric-coated tablet formulations.

Standard Tablets (Salazopyrin)

The standard (uncoated) Salazopyrin tablet contains the following excipients: pregelatinized corn starch (binder/filler), magnesium stearate (lubricant), povidone (binder), and colloidal anhydrous silica (glidant). The tablet is yellow, biconvex, with a score line, approximately 13.5 mm in diameter, and has an engraved symbol. The yellow color is inherent to the sulfasalazine compound itself, not from added colorants.

Enteric-Coated Tablets (Salazopyrin EN)

Salazopyrin EN (enteric-coated) tablets contain the same active ingredient and core excipients as the standard tablets, with an additional enteric coating. This coating is designed to resist dissolution in the acidic environment of the stomach (pH < 5) and dissolve in the more alkaline environment of the small intestine (pH > 6). The enteric coating typically consists of methacrylic acid copolymer (such as Eudragit), triethyl citrate (plasticizer), and talc. This formulation was developed to reduce the nausea and gastric irritation commonly experienced with the standard tablets.

If you have known allergies to any excipients, particularly corn starch derivatives, always check the specific product’s patient information leaflet or consult your pharmacist before taking the medication. Sulfasalazine tablets do not contain lactose, gluten, or aspartame.